Cynata Therapeutics Ltd (ASX: CYP) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cynata Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cynata Therapeutics Ltd (ASX: CYP)
Latest News
Healthcare Shares
Here's why the Cynata (ASX:CYP) share price is rising today
Healthcare Shares
Are these 4 ASX medical shares set for a healthy 2021?
Share Market News
Cynata Therapeutics share price jumps 14% on COVID-19 trial
Share Gainers
Why Cynata, Fluence, Food Revolution, & Fortescue are pushing higher
Share Gainers
Why this small cap biotech ASX share zoomed higher on Tuesday
Share Market News
Why the Cynata Therapeutics share price is up 10% today
Share Fallers
Why the Cynata share price crashed 15% lower today
Share Gainers
Why Cynata, Medical Developments International, NAB, & Resolute charged higher
Share Gainers
ASX small caps outperform on the Aussie dollar strength and rate cut bets
Share Gainers
Cynata Therapeutics share price rockets higher on takeover news
Share Gainers
These small cap ASX shares are surging higher today
⏸️ Investing
5 ASX shares to build a portfolio around
CYP ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Cynata Therapeutics Ltd
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinicaltrials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.
CYP Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
03 Dec 2024 | $0.22 | $-0.02 | -8.70% | 67,953 | $0.23 | $0.23 | $0.22 |
02 Dec 2024 | $0.23 | $0.02 | 9.30% | 50,922 | $0.23 | $0.23 | $0.23 |
29 Nov 2024 | $0.22 | $0.00 | 0.00% | 25,000 | $0.22 | $0.22 | $0.22 |
28 Nov 2024 | $0.22 | $0.00 | 0.00% | 14,197 | $0.22 | $0.22 | $0.22 |
27 Nov 2024 | $0.22 | $0.00 | 0.00% | 170,306 | $0.22 | $0.22 | $0.21 |
26 Nov 2024 | $0.22 | $-0.01 | -4.55% | 10,833 | $0.22 | $0.22 | $0.22 |
25 Nov 2024 | $0.22 | $0.01 | 4.65% | 24,754 | $0.22 | $0.22 | $0.22 |
22 Nov 2024 | $0.22 | $0.00 | 0.00% | 33 | $0.22 | $0.22 | $0.22 |
21 Nov 2024 | $0.22 | $0.00 | 0.00% | 26,500 | $0.22 | $0.22 | $0.22 |
20 Nov 2024 | $0.21 | $-0.01 | -4.55% | 131,955 | $0.22 | $0.22 | $0.21 |
19 Nov 2024 | $0.22 | $-0.01 | -4.44% | 146,340 | $0.23 | $0.23 | $0.22 |
18 Nov 2024 | $0.23 | $-0.02 | -8.16% | 143,180 | $0.25 | $0.25 | $0.23 |
15 Nov 2024 | $0.25 | $0.01 | 4.26% | 63,985 | $0.24 | $0.25 | $0.24 |
14 Nov 2024 | $0.24 | $-0.01 | -4.17% | 3,999 | $0.24 | $0.24 | $0.24 |
13 Nov 2024 | $0.24 | $0.01 | 4.26% | 147,754 | $0.23 | $0.24 | $0.23 |
12 Nov 2024 | $0.24 | $0.02 | 9.09% | 299,858 | $0.22 | $0.24 | $0.22 |
11 Nov 2024 | $0.22 | $0.00 | 0.00% | 71,000 | $0.23 | $0.23 | $0.22 |
08 Nov 2024 | $0.22 | $0.00 | 0.00% | 131,999 | $0.22 | $0.23 | $0.22 |
07 Nov 2024 | $0.22 | $0.00 | 0.00% | 88,223 | $0.23 | $0.23 | $0.22 |
06 Nov 2024 | $0.22 | $-0.01 | -4.44% | 99,909 | $0.23 | $0.23 | $0.22 |
05 Nov 2024 | $0.23 | $-0.01 | -4.35% | 147,755 | $0.23 | $0.23 | $0.23 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
16 May 2024 | Geoffrey Brooke | Expiry | 300,000 | $84,000 |
Options expired.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr Paul K Wotton | Non-Executive Director | Jun 2016 |
Mr Wotton was the Chief Executive Officer of Obsidian Therapeutics, a clinical stage TIL therapy company based in Cambridge, Massachusetts. Prior to this, he was the Founding President and CEO of Sigilon Inc. Dr Wotton held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme. Dr Wotton is a member of the Board and Governance Committee of Vericel Corporation (NASDQA: VCEL), a US company developing autologous cellular therapies, Chairman of Kytopen Corp., an MIT startup focused on non-viral transduction technology, independent director at Dimension Inx, a biomaterials platform company and Founder of AvengeBio, a clinical stage immune oncology company focused on ovarian and peritoneal cancers. In 2014, he was named New Jersey EY Entrepreneur of the Year in Life Sciences.
|
Mr Peter Webse | Company Secretary | May 2012 |
Mr Webse has over 28 years company secretarial experience and is the managing director of Platinum Corporate Secretariat Pty Ltd, a company specialising in providing company secretarial, corporate governance and corporate advisory services.
|
Dr Geoffrey E.D Brooke | Non-Executive DirectorNon-Executive Chairman | May 2019 |
Mr Brooke has joined the Board in May 2019 as Non-Executive Director and appointed Chair on 18 August 2020.Dr Brooke co-founded GBS Venture Partners in 1996 and has more than 30 years of venture capital experience. He was formerly President of Medvest Inc.a US-based early-stage venture capital group he founded with Johnson & Johnson. Dr Brooke's experience includes company formation and acquisitions as well as public listings on NYSE, NASDAQ and ASX exchanges. From 2009 until 2015, Dr Brooke was an independent director of the Victoria Workcover Authority.
|
Mrs Janine Rolfe | Non-Executive Director | Sep 2022 |
Ms Rolfe brings more than two decades of legal, governance and management experience across multiple sectors, including highly regulated industries and complex global businesses. Ms Rolfe is a professional non-executive director and currently sits on the boards of Ambertech Limited (ASX: AMO) and Cloudwerx Holdings Pty Ltd. Ms Rolfe is also a commissioner for the NSW Independent Casino Commission, a statutory authority. Previously, Ms Rolfe was General Counsel & Company Secretary of Link Group. Prior to that, Ms Rolfe founded the governance consultancy, Company Matters, and worked both as in-house counsel at Qantas and in private practice at Mallesons Stephen Jaques (now King & Wood Mallesons).
|
Dr Darryl Maher | Non-Executive Director | Jun 2020 |
Mr Maher adds global biopharmaceutical and commercialization capability to the Cynata board, with over 23 years of experience with CSL Limited. CSL is one of the world's most successful developers of biologic pharmaceutical products and has a market capitalization of ~A$130 billion. Dr Maher has had a long career in pharmaceutical product development, most recently as the former Vice President of R&D and Medical Affairs at CSL Behring Australia where he was responsible for the development of multiple successful drug products from initiation through to clinical development and ultimately to commercialization. Dr Maher undertook medical training, qualified as a specialist hematologist.
|
Dr Kilian Kelly | Chief Executive OfficerManaging Director | Jul 2023 |
Dr Kelly has served as Senior Director, Drug Development at Biota Pharmaceuticals Inc. Prior to joining Biota, he was Vice President, Regulatory and Clinical at Mesoblast Ltd. Dr Kelly has also held a variety of regulatory and project management positions with Kendle International, Amgen and AstraZeneca. He is a registered pharmacist and a member of the Royal Pharmaceutical Society, a graduate and member of the Australian Institute of Company Directors (AICD), a member of the International Society for Cell and Gene Therapy (ISCT) and the International Society for Stem Cell Research (ISSCR). He also currently serves on the ISCT Asia-Pacific Industry Committee, the ISSCR Best Practices Regulatory Working Group and the Industry Interface Committee of the Centre for Commercialization of Regenerative Medicine (CCRM) Australia.
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Phillip Asset Management Limited <Bioscience MTF1 A/C> | 23,588,040 | 13.06% |
HSBC Custody Nominees (Australia) Limited | 14,731,445 | 8.16% |
Fujifilm Corporation | 8,088,403 | 4.48% |
Citicorp Nominees Pty Limited | 6,591,672 | 3.65% |
BNP Paribas Nominees Pty Ltd <IB AU Noms Retailclient> | 4,323,767 | 2.39% |
Kenneth Adrian Raymond Wilson | 3,549,905 | 1.97% |
BNP Paribas Nominees Pty Ltd <Clearstream> | 3,039,266 | 1.68% |
Mrs Aily Lamb | 2,360,000 | 1.31% |
J P Morgan Nominees Australia Pty Limited | 2,025,850 | 1.12% |
Dr Ross Alexander Macdonald | 2,000,000 | 1.11% |
National Nominees Limited | 1,780,000 | 0.99% |
Mr Craig Lawrence Darby | 1,729,477 | 0.96% |
BNP Paribas Noms Pty Ltd | 1,684,988 | 0.93% |
Mal Washer Nominees Pty Ltd <Mal Washer Family A/C> | 1,559,534 | 0.86% |
Mr Pawel Rej & Mrs Miroslawa Rej | 1,543,036 | 0.85% |
Crosswind Trustee Company Limited <Crosswind A/C> | 1,513,000 | 0.84% |
Mr Patrick Anthony Walsh | 1,341,790 | 0.74% |
Souttar Superannuation Pty Ltd <Greenslade Super Fund A/C> | 1,330,000 | 0.74% |
Mr Jon Nicolai Bjarnason & Mrs Rina Eghoje Bjarnason <Jarck Super Fund A/C> | 1,311,034 | 0.73% |
Dr Maksym Vodyanyk | 1,191,658 | 0.66% |